When a lab receives your urine sample, it goes through a two-stage process: a fast, inexpensive screening test that flags potential positives, followed by a more precise confirmatory test that identifies exactly what’s in the sample. Most results come from immunoassay screening, which uses antibodies to detect drug classes. Only samples that screen positive move on to the second stage.
Step One: The Immunoassay Screen
The initial screening test is an immunoassay, a technique that relies on antibodies designed to react with specific drugs or their breakdown products. These tests are fast, relatively cheap, and can process large volumes of samples. The basic idea: antibodies in the test kit are programmed to bind to a target drug. If that drug is present above a certain concentration threshold, the test produces a measurable signal.
There are a few common formats. In one widely used version (enzyme-multiplied immunoassay), an enzyme is paired with a drug-like molecule and mixed with antibodies. When no drug is present, the antibodies latch onto the enzyme and block it from working. When the real drug is in the sample, the antibodies grab the free drug instead, leaving the enzyme unblocked. The more drug in the sample, the more enzyme activity the lab can measure.
Another format works like a home pregnancy test. Tiny colored beads coated with antibodies are drawn across a test strip. If no drug is present, the beads get trapped at a specific zone on the strip, producing two colored lines (a negative result). If the drug is present, the beads flow past that zone, leaving only one line (a positive result). These lateral flow strips are the technology behind most point-of-care and rapid drug tests.
Immunoassays detect drug classes, not individual drugs. A test for opioids reacts to a broad group of structurally similar compounds, not specifically to hydrocodone versus oxycodone. This means they cast a wide net, which is useful for screening but comes with a significant limitation: false positives.
Why Screening Tests Get It Wrong
Because immunoassays work by recognizing molecular shapes, any substance with a similar structure to the target drug can trigger a positive. This is called cross-reactivity, and it happens more often than most people realize. Amphetamine screens are especially prone to false positives because the amphetamine molecule is so simple that many common medications share its basic structure.
Some notable offenders:
- Amphetamine false positives: pseudoephedrine (Sudafed), bupropion (Wellbutrin), phentermine (weight loss medication), methylphenidate (Ritalin), ranitidine, trazodone
- Opioid false positives: poppy seeds, dextromethorphan (cough suppressants), diphenhydramine (Benadryl), verapamil (blood pressure medication)
- PCP false positives: dextromethorphan, diphenhydramine, ketamine, tramadol, venlafaxine (Effexor)
- Marijuana false positives: ibuprofen, naproxen, efavirenz, and certain baby wash products
- Benzodiazepine false positives: sertraline (Zoloft), oxaprozin (an anti-inflammatory), efavirenz
This is exactly why a positive immunoassay screen is never treated as a final answer in any legally defensible testing program. It’s considered a “presumptive positive” that requires confirmation.
Step Two: Confirmatory Testing
When a sample screens positive, it moves to a second test using either gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS). These instruments don’t rely on antibodies. Instead, they physically separate all the molecules in a sample and identify each one by its unique chemical fingerprint.
In chromatography, the urine sample is pushed through a long, thin column. Different molecules travel through the column at different speeds depending on their physical properties, so they exit one at a time. As each molecule comes out, it enters the mass spectrometer, which breaks it into fragments and measures the weight and charge of each fragment. The resulting pattern is essentially a molecular fingerprint that can distinguish between, say, methamphetamine and pseudoephedrine, even though they look identical to an immunoassay.
GC-MS has been the gold standard for decades but requires more preparation. The sample needs to be cleaned up, concentrated, and chemically modified so the drug molecules can be vaporized. LC-MS skips several of these steps because it works with liquid samples directly, making it faster and better suited for certain drugs that don’t vaporize easily. Both methods can identify and measure specific drugs at very low concentrations.
What the Lab Actually Looks For
Your body doesn’t excrete most drugs in their original form. The liver breaks them down into metabolites, and those metabolites are what the kidneys filter into urine. Labs test for specific metabolites rather than (or in addition to) the parent drug, which is why detection windows extend well beyond the time you’d feel a drug’s effects.
For marijuana, the lab looks for a metabolite called THC-COOH, not THC itself. For cocaine, the target is benzoylecgonine, a breakdown product that stays in the body much longer than cocaine does. For heroin, the lab searches for morphine and codeine (heroin breaks down into both) as well as a unique marker called 6-acetylmorphine that distinguishes heroin use from other opioid use.
Because urine concentration varies throughout the day depending on hydration, labs often divide the drug metabolite concentration by the creatinine level in the sample. This normalization helps distinguish a truly negative sample from one that’s just very dilute. For marijuana in particular, comparing creatinine-normalized THC ratios across multiple tests can help determine whether someone used the drug recently or whether an older positive is still clearing from the body.
Cutoff Levels That Determine Positive or Negative
A drug test isn’t simply “detected” or “not detected.” Each test has a cutoff concentration, measured in nanograms per milliliter (ng/mL), and anything below that cutoff is reported as negative even if trace amounts are present. Federal workplace testing guidelines set these thresholds, and most private employers follow them.
The screening cutoff is intentionally set higher than the confirmatory cutoff, which acts as a wider net. For marijuana metabolites, the initial screen cutoff is 50 ng/mL, while confirmation drops to 15 ng/mL. For cocaine metabolites, screening is at 150 ng/mL and confirmation at 100 ng/mL. Amphetamine screening uses 500 ng/mL, with confirmation at 250 ng/mL. Fentanyl has the lowest threshold of any standard panel drug: just 1 ng/mL for both screening and confirmation, reflecting both its extreme potency and growing prevalence.
These cutoffs explain why two people who used the same substance can get different results. Someone right at the threshold could test positive one day and negative the next depending on hydration, metabolism, and timing.
How Long Drugs Stay Detectable
Detection windows vary enormously depending on the substance, how often it’s used, and individual metabolism. Marijuana has the widest range: a single use may be detectable for 1 to 3 days, while daily, heavy use can show up for up to 30 days because THC metabolites accumulate in fat tissue and release slowly. Cocaine typically clears in 2 to 4 days for casual use, but heavy use can extend that window to 10 to 22 days.
Most other drugs have shorter windows. Amphetamines and methamphetamine clear in 1 to 2 days. Heroin, codeine, morphine, and fentanyl are generally detectable for only 1 to 2 days. Oxycodone has a particularly short window of about 1 to 1.5 days. Benzodiazepines vary dramatically depending on the specific drug: short-acting types clear in 1 to 3 days, while long-acting types with heavy use can linger up to 6 weeks. Methadone falls in between at 2 to 11 days.
How Labs Catch Tampered Samples
Labs run specimen validity tests on every sample before performing drug analysis. They check three properties: pH (acidity), creatinine concentration, and specific gravity (a measure of how concentrated the urine is). Normal human urine falls within predictable ranges for all three. A sample with an extremely low creatinine level suggests dilution, either by drinking excessive water or by adding water to the sample. An unusual pH can indicate someone added bleach, vinegar, or another adulterant. Specific gravity outside the normal range reinforces evidence of dilution or substitution.
A sample flagged as dilute, substituted, or adulterated is typically reported as invalid, and the person is asked to provide a new sample under direct observation.
Chain of Custody
For any test with legal consequences (workplace, legal, military), the sample follows a strict chain of custody from the moment it leaves your body. The collection container gets a unique identification code, and a form travels with the sample documenting every person who handles it, the date and time of each transfer, and the storage conditions in between. You sign the label at collection, the collector signs, and every subsequent handler signs when they receive and release the sample. The container is sealed in tamper-evident packaging.
This documentation exists so that if a result is challenged in court or an administrative hearing, there’s a clear, unbroken record proving the sample wasn’t accessed by unauthorized people or altered after collection.
The Limits of Standard Panels
Standard immunoassay panels typically test for a defined list: marijuana, cocaine, opioids, amphetamines, PCP, and (in federal testing) fentanyl and MDMA. But they can miss entire categories of drugs. Synthetic cannabinoids (sold as “K2” or “Spice”) don’t trigger a positive on a standard marijuana screen because their molecular structure is completely different from THC. Traditional color-based chemical tests also fail to detect them. Some specialized immunoassay kits can detect older synthetic cannabinoids, but newer designer compounds stay ahead of available tests.
Synthetic stimulants like bath salts (cathinones) are similarly invisible to standard screens. No commercial immunoassay reliably detects them. Identifying these substances requires LC-MS analysis, and even then, labs need reference data for each specific compound. Because manufacturers constantly tweak the molecular structure to stay ahead of regulations, there’s an ongoing gap between what’s being used and what labs can readily identify.